Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsAs an expert in antibody development, Creative Biolabs has successfully completed a lot of customized antibody projects. Focused on the efficient therapy discovery, we recently have made great progress in agonistic/antagonistic antibodies-based immunotherapy. Our professional scientists are excited to offer our off-the-shelf products and services to help you get landmark development.
Antibody is a class of immunoglobulins produced by the immune system that functions to eliminate antigens by binding to relevant Fc receptors. As a kind of glycoproteins, antibodies also bind to other receptors and causing downstream signaling activation or inhibition, which is known as agonistic or antagonistic antibodies.
Antagonistic antibodies are monoclonal antibodies that block effector response (namely antagonistic effect) by bind to the receptor. Actually, antagonistic antibodies mediate antagonist activity in a manner that blocks or dampen the binding of the natural ligand to the receptor. Currently, a number of approved antagonistic antibodies have been applied for the treatment of cancers by the mechanism of reverse immune resistance of tumors.
Antagonistic antibodies exhibit great value in human disorder treatment, specifically, those antibodies targeting negative immune checkpoints receptors exert potent anti-tumor activity in vitro.
As one of the most aggressive skin tumor, melanoma is affecting more and more people all over the world. In recent years, immune checkpoint inhibitors or immune checkpoint antagonistic antibodies as new immunotherapies have been approved by Food and Drug Administration (FDA) for the treatment of advanced melanoma, such as anti-programmed cell death protein 1 (PD-1) antibodies pembrolizumab, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies tremelimumab.
Fig.1 Mode of action of CTLA-4 or PD-1 inhibitors in tumor immunotherapy. (Franklin, 2017)
Lung cancer is a malignant tumor in lung tissue. The increasing morbidity and mortality of lung cancer make it necessary and urgently to find out effective therapies. Several antagonist antibodies to PD-1, programmed cell death ligand 1 (PD-L1), and CTLA4 are undergoing pre-clinical evaluations and have shown considerable therapeutic effects on lung cancer.
NSCLC, a typical kind of epithelial cancer accounts for approximately 85% of lung cancers, is a metastatic tumor that can spread to the nearby tissues and cells with the tumor progresses. Compared with conventional therapies, like surgery, chemotherapy, and radiation therapy, immunotherapy, particularly antagonist antibody-based treatment has been demonstrated to be effective against NSCLC.
As the most prevalent kidney cancer, RCC is a malignant tumor originating from the inner wall of proximal convoluted tubules. Recently, immunotherapy based on immune checkpoints antagonist antibody has revolutionized RCC treatment with significant clinical efficacy.
Tumors that arise from squamous cells are squamous cell carcinomas, also referred to epidermoid carcinomas. About 90%-95% head and neck cancers are SCCHN. Antagonist antibodies, such as anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab, have been widely used for the treatment of SCCHN.
As your best partner, Creative Biolabs utilizes many advanced antibody technologies to provide comprehensive antibody services for our clients from all over the world, especially the clients who are currently having difficulty working on the agonistic and antagonistic antibody.
If you are interested, please directly contact us or send us an inquiry.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
